Immunology and immunotherapy in breast cancer

Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies have already been studied in many clinical trials on various tumor types. In recent years, a checkpoint inhibition therapy with monoclonal antibodies targeting PD-1 and its ligand PD-L1 has been developed. Breast c...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer biology & medicine Vol. 19; no. 5; pp. 609 - 618
Main Authors:	Semiglazov, Vladimir, Tseluiko, Andrey, Kudaybergenova, Asel, Artemyeva, Anna, Krivorotko, Petr, Donskih, Roman
Format:	Journal Article
Language:	English
Published:	China Petrov National Medicine Cancer-Research Center Ministry of Health,Saint-Petersburg 197758,Russia 09-06-2022 Compuscript China Anti-Cancer Association
Subjects:	breast cancer immunotherapy pd-1 pd-l1 Review tumor-infiltrating lymphocytes PD-L1 tumor-infiltrating lymphocytes Breast cancer PD-1 immunotherapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies have already been studied in many clinical trials on various tumor types. In recent years, a checkpoint inhibition therapy with monoclonal antibodies targeting PD-1 and its ligand PD-L1 has been developed. Breast cancer had been examined in the field of immune-oncology relatively recently. This review focuses on clinical evidence regarding immune checkpoint inhibition for curative treatment of various breast cancer subtypes. In addition, we present the results of studies demonstrating the prognostic and predictive value of levels of tumorinfiltrating lymphocytes (CD4 and CD8), their quantitative ratios, and their correlation with regulatory genes (PD-1, PD-L1, and FOX-P3).
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2095-3941
DOI:	10.20892/j.issn.2095-3941.2021.0597